Navigation Links
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
Date:7/7/2011

AMSTERDAM, July 7, 2011 /PRNewswire/ --


Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera® with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy,""expects,"" plans,""anticipates,""believes, ""will,""continues," "estimates,""intends,"" projects,""goals,""targets " and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
2. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
10. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
11. NIH grant ratchets up ASU research in molecular motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... ... , ... Tunnell Consulting has been solving the most complex problems ... faced by life sciences, biotech and pharmaceuticals companies today is in interpreting the complicated ... who is well known in the industry and brings significant high-level expertise to the ...
(Date:6/16/2017)... ... ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced the ... Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and entrepreneurs, ... secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... promising new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served ... and this angelMD syndicate is part of Saranas’ recently announced $4 million Series ...
(Date:6/14/2017)... Bangkok, Thailand (PRWEB) , ... June 14, 2017 ... ... Thailand Center of Excellence for Life Sciences (TCELS) announces that they’re co-hosting a ... 19-22, 2017. , BIO, the largest biotech industry gathering in the world, ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):